Despite marked progress in the lymphoma treatment landscape, the prognosis of patients with relapsed and/or refractory disease remains poor; thus, a continued need exists for the development of innovative approaches and therapies. Epigenetic dysregulation may drive and/or promote tumorigenesis in various malignancies and is prevalent in both B-cell and T-cell lymphomas. Over the past decade, a large number of epigenetic-modifying agents have been developed and introduced into the clinical management of patients with hematological malignancies. This podcast features Ari Melnick, MD, of the Weill Cornell Medical College, New York, NY. The footage included is from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.